US 11,944,639 B2
Preventive and curative peroxometallate based composition, notably pharmaceutical composition
Rémi Wilmotte, Chalons-sur-Vesles (FR); Frédéric Lorenzo, Seine-Port (FR); and Denis Olivier Chretien, La Garenne Colombes (FR)
Assigned to OXYMO TECHNOLOGIES INC., Québec (CA)
Filed by OXYMO TECHNOLOGIES INC., Québec (CA)
Filed on Oct. 16, 2020, as Appl. No. 17/073,026.
Application 17/073,026 is a continuation of application No. 16/089,757, granted, now 10,857,179, previously published as PCT/IB2017/051797, filed on Mar. 29, 2017.
Claims priority of application No. 16 52697 (FR), filed on Mar. 29, 2016.
Prior Publication US 2021/0030788 A1, Feb. 4, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 33/24 (2019.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 33/242 (2019.01); A61K 33/244 (2019.01); A61K 33/40 (2006.01); A61K 47/08 (2006.01); A61K 47/18 (2017.01); A61P 31/22 (2006.01)
CPC A61K 33/24 (2013.01) [A61K 9/0014 (2013.01); A61K 9/0034 (2013.01); A61K 9/0048 (2013.01); A61K 9/006 (2013.01); A61K 9/08 (2013.01); A61K 33/242 (2019.01); A61K 33/244 (2019.01); A61K 33/40 (2013.01); A61K 47/08 (2013.01); A61K 47/183 (2013.01); A61P 31/22 (2018.01)] 31 Claims
 
1. A topical pharmaceutical composition, wherein said composition comprises or consists of a therapeutically active mixture comprising:
from 0.1 to 100 μM of metal salt of molybdenum;
at least one chelating agent;
at least one source of peroxidizing radicals;
at least one buffering agent,
wherein said composition or mixture has a redox potential from 250 to 550 millivolts.